SR9009 (Stenabolic) is a synthetic REV-ERBα agonist developed by researchers at the Scripps Research Institute as a tool compound for studying circadian-rhythm biology and metabolism.
🔬 Studied for: Circadian-Rhythm Research
💊 Also studied for: Metabolic Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
SR9009 (Stenabolic) is a synthetic REV-ERBα agonist developed by researchers at the Scripps Research Institute as a tool compound for studying circadian-rhythm biology and metabolism. Despite its bodybuilding-community nickname, it is not a SARM and does not interact with the androgen receptor.
SR9009 activates REV-ERBα, a nuclear receptor central to the molecular circadian clock that also regulates genes involved in lipid metabolism, mitochondrial biogenesis, and inflammatory pathways — its research relevance stems primarily from chronobiology, not androgen signaling.
These are effects SR-9009 (Stenabolic) has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
SR9009 was originally developed as a tool compound to probe REV-ERB's role in the molecular clock, and remains widely used in that specific area of academic chronobiology research rather than as a developed drug candidate.
Preclinical studies in mice have investigated SR9009's effects on running endurance, energy expenditure, and lipid metabolism, which is the basis for its research-community popularity, though its poor bioavailability is a frequently cited limitation of these findings translating to oral human use.
No FDA-approved or clinically validated human dosage exists for SR9009. Doses used in mouse studies are documented in that specific preclinical literature and do not translate to a human protocol.
Compound X does not provide dosing recommendations. SR-9009 (Stenabolic) is sold for laboratory research use only and is not intended for human consumption.
SR9009 has not advanced past preclinical animal research and has no completed human clinical trials, no established human safety data, and no FDA approval. Its very short elimination half-life and bioavailability issues are additional reasons it has not been developed further pharmaceutically.
No. SR-9009 (Stenabolic) is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Circadian-Rhythm Research — SR9009 was originally developed as a tool compound to probe REV-ERB's role in the molecular clock, and remains widely used in that specific area of academic chronobiology research rather than as a developed drug candidate.
In the US, UK, Canada and Australia, SR-9009 (Stenabolic) is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
SR9009 research is indexed on PubMed under search terms such as "SR9009 REV-ERB agonist" and "Stenabolic circadian nuclear receptor."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.